Nadixa (Nadifloxacin)

Nadifloxacin, the active ingredient in Nadixa, is a fluoroquinolone presented as a topical preparation for skin application. It is used to treat acne vulgaris and secondary bacterial skin infections in patients requiring topical antibacterial therapy.

GNH USA supplies Nadixa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nadixa is indicated for bacterial skin conditions where topical antibacterial action is required.

- Acne vulgaris: reduces inflammatory lesions and bacterial colonisation on the skin. - Secondary bacterial skin infections: treats infection of compromised skin caused by susceptible bacteria. - Post‑procedural skin inflammation: helps prevent bacterial overgrowth after dermatologic procedures.

Nadixa may cause local and systemic adverse reactions.

Common Side Effects: - Skin irritation: mild redness or itching at the application site. - Dryness: localized skin dryness or peeling. - Burning sensation: transient burning feeling after application. - Pruritus: occasional itching of the treated area. - Erythema: mild redness of the skin.

Serious or Rare Side Effects: - Allergic reaction: rash, swelling, or hives indicating hypersensitivity. - Stevens‑Johnson syndrome: rare severe skin reaction requiring immediate medical attention. - Toxic epidermal necrolysis: extremely rare, life‑threatening skin detachment. - Photosensitivity: increased sensitivity to sunlight leading to severe sunburn. - Systemic absorption effects: rare systemic fluoroquinolone‑related events such as tendonitis.

When using Nadixa, consider the following safety measures.

- Contraindication: Do not apply to patients with known hypersensitivity to nadifloxacin or other fluoroquinolones. - Pregnancy: Use only if the prescriber determines potential benefit outweighs risk; safety data are limited. - Breastfeeding: Caution advised; discuss with a healthcare professional before use. - Extensive skin damage: Avoid use on large areas of damaged or ulcerated skin. - Sun exposure: Advise patients to limit UV exposure and use sunscreen on treated areas. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Nadixa may interact with other agents applied to the skin or systemic fluoroquinolones.

Major Interactions (Avoid): - Systemic fluoroquinolones: concurrent use may increase risk of systemic toxicity. - Topical corticosteroids: may reduce antibacterial efficacy and increase irritation.

Moderate Interactions (Monitor Closely): - Other topical antibiotics: assess for additive irritation or resistance. - Photosensitizing agents: monitor for enhanced photosensitivity reactions. - Antacids or mineral supplements: unlikely with topical use but consider if systemic absorption occurs.